TSE:4516Pharmaceuticals
Nippon Shinyaku (TSE:4516): Valuation Insights Following Positive Brogidirsen Clinical Results
Nippon Shinyaku (TSE:4516) shares are in focus after its subsidiary NS Pharma released 3.5-year clinical data on brogidirsen for Duchenne muscular dystrophy. The results highlighted stable motor function and a favorable safety overview in treated participants.
See our latest analysis for Nippon Shinyaku.
While news of brogidirsen’s progress has put a spotlight on Nippon Shinyaku, the share price has yet to show positive momentum, with a year-to-date decline of 19.6% and a one-year total...